Valuation: Castle Biosciences, Inc.

Market Cap 1.02B 910M 842M 762M 1.43B 96.79B 1.45B 10.13B 4.01B 50.62B 3.82B 3.74B 160B P/E 2026 *
-26.5x
P/E 2027 * -36.5x
Enterprise Value 1.02B 910M 842M 762M 1.43B 96.79B 1.45B 10.13B 4.01B 50.62B 3.82B 3.74B 160B EV / Sales 2026 *
2.72x
EV / Sales 2027 * 2.47x
Free-Float
97.64%
Yield 2026 *
-
Yield 2027 * -
10-12 Castle Biosciences, Inc. Announces New Data from Three Studies Evaluating Its TissueCypher Barrett's Esophagus Test at ACG 2026 CI
09-30 Castle Biosciences, Inc. Presents New Data On DecisionDx-Melanoma At The European Academy Of Dermatology And Venereology Congress 2026 CI
09-24 Castle Biosciences, Inc. Announces Publication of New Study Highlighting Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of Advancead-Tx CI
09-22 Castle Biosciences to Open New Lab in Arizona MT
09-22 Castle Biosciences, Inc. Opens New Laboratory and Office Facility in Scottsdale, Arizona CI
09-15 Castle Biosciences Publishes Decision Modeling Study Demonstrating Tissuecypher Barrett's Esophagus Test Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus CI
09-09 Castle Biosciences, Inc. Announces Enhanced Performance Of DecisionDx-SCC With Integration Of Clinicopathologic Risk Factors CI
08-27 Castle Biosciences Insider Sold Shares Worth $317,112, According to a Recent SEC Filing MT
08-17 Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas MT
07-31 Castle Biosciences, Inc., Q2 2026 Earnings Call, Jul 30, 2026
07-30 Earnings Flash (CSTL) Castle Biosciences Posts Q2 Revenue of $103.5 Million, vs. FactSet Est of $86.2 Million MT
07-30 Earnings Flash (CSTL) Castle Biosciences Posts Q2 Adjusted EPS -$0.07, vs. FactSet Est of -$0.41 MT
07-30 Castle Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
1 day+0.67%
1 week+3.53%
Current month-6.28%
1 month-7.01%
3 months+34.90%
6 months+36.14%
Current year-14.40%
1 week 32.69
Extreme 32.69
34.72
1 month 31.67
Extreme 31.67
37.99
Current year 17.72
Extreme 17.722
44.28
1 year 17.72
Extreme 17.722
44.28
3 years 12.95
Extreme 12.95
44.28
5 years 9.26
Extreme 9.2601
65.72
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 2007-08-31
Director of Finance/CFO 56 2017-11-30
Chief Tech/Sci/R&D Officer - 2021-06-30
Director TitleAgeSince
Director/Board Member 64 2007-08-31
Chairman 64 2014-08-31
Director/Board Member 70 2018-12-05
Date Insider Type Main position Quantity % Market Cap. Importance
10/12/26 Sell

Executive/Senior Manager

-3,288 0.0108%
10/5/26 Exercice

Founder

30,826 0.1009%
10/1/26 Exercice

Chief Operating Officer

12,459 0.0408%
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%+3.53%+35.86%+154.59% 1.01B
+1.14%+0.79%-17.32%+11.60% 179B
-0.33%+2.75%-19.82%+18.39% 118B
-0.65%+2.18%+1.20%+34.70% 117B
-3.42%+15.09%-44.16%+5.61% 93.26B
-0.30%-2.94%-0.81%+74.97% 63.16B
+1.32%+1.77%+8.65%+82.48% 55.68B
-1.27%+2.96%+5.68%-22.74% 54.18B
+1.75%+2.59%-11.02%+43.47% 44.15B
+0.03%+6.23%-5.17%-7.53% 33.95B
Average -0.11%+3.46%-4.69%+39.55% 75.94B
Weighted average by Cap. -0.22%+3.31%-12.26%+24.68%

Financials

2026 *2027 *
Net sales 373M 334M 309M 280M 524M 35.53B 532M 3.72B 1.47B 18.58B 1.4B 1.37B 58.84B 412M 369M 341M 309M 578M 39.24B 588M 4.11B 1.62B 20.52B 1.55B 1.51B 64.99B
Net income -37.43M -33.47M -30.97M -28.04M -52.48M -3.56B -53.34M -373M -147M -1.86B -140M -137M -5.9B -24.56M -21.97M -20.32M -18.4M -34.44M -2.34B -35M -245M -96.73M -1.22B -92.2M -90.23M -3.87B
Net Debt - -
Projected Income Statement - Annual - Castle Biosciences, Inc.
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
1,002
Date Price Change Volume
26-10-26 US$33.30 +0.67% 235,840
26-10-23 US$33.08 -0.33% 203,016
26-10-22 US$33.19 -3.43% 335,419
26-10-21 US$34.37 +3.68% 336,592
26-10-20 US$33.15 +3.06% 272,493
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Castle Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
33.30USD
Average target price
45.22USD
Spread / Average Target
+35.80%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Castle Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. CSTL Stock